TIDMHEMO
RNS Number : 6159E
Hemogenyx Pharmaceuticals PLC
30 June 2023
30 June 2023
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at
the Annual General Meeting ("AGM") held earlier today, all
resolutions were duly passed on a show of hands. The numbers of
proxy votes for each resolution submitted prior to the meeting are
presented below.
Proxy Voting Results
Ordinary Resolutions Votes % of Votes % of Total Total Votes
for votes Against votes votes votes with-held
cast for cast cast cast as (2)
against % of ISC
(1)
1. To adopt the
2022 Annual Report
and Accounts 187,231,295 99.86 260,529 0.14 187,491,824 16.42 4,905,675
------------ ---------- ----------- --------- ------------ ---------- -----------
2. To approve
the Directors'
Remuneration Policy 175,511,893 91.34 16,644,001 8.66 192,155,894 16.83 241,605
------------ ---------- ----------- --------- ------------ ---------- -----------
3. To re-appoint
Peter Redmond
as Director 161,957,826 86.38 25,531,232 13.62 187,489,058 16.42 4,908,441
------------ ---------- ----------- --------- ------------ ---------- -----------
4. To re-appoint
Alexis Sandler
as Director 175,078,447 93.44 12,285,451 6.56 187,363,898 16.41 5,033,601
------------ ---------- ----------- --------- ------------ ---------- -----------
5. To re-appoint
Dr Vladislav Sandler
as Director 175,160,284 93.49 12,203,614 6.51 187,363,898 16.41 5,033,601
------------ ---------- ----------- --------- ------------ ---------- -----------
6. To reappoint
the Company's
auditor 185,776,647 99.09 1,715,177 0.91 187,491,824 16.42 4,905,675
------------ ---------- ----------- --------- ------------ ---------- -----------
7. To authorise
the Audit Committee
to determine the
auditor's remuneration 176,309,143 94.04 11,179,915 5.96 187,489,058 16.42% 4,908,441
------------ ---------- ----------- --------- ------------ ---------- -----------
8. To authorise
the Directors
to allot equity
securities 170,229,487 90.79 17,259,571 9.21 187,489,058 16.42 4,908,441
------------ ---------- ----------- --------- ------------ ---------- -----------
Special Resolutions Votes % of Votes % of Total Total Votes
for votes against votes votes votes with-held
cast for cast cast cast as (2)
against % of ISC
(1)
------------ ---------- ----------- --------- ------------ ---------- -----------
9. To disapply
pre-emption provisions 156,025,169 89.79 17,751,132 10.21 173,776,301 15.22 18,621,198
------------ ---------- ----------- --------- ------------ ---------- -----------
10. To reduce
the notice period
for general meetings 171,582,521 91.51 15,909,303 8.49 187,491,824 16.42 4,905,675
------------ ---------- ----------- --------- ------------ ---------- -----------
(1) The Company's issued share capital (" ISC") on 28 June 2023,
being the date on which members had to be entered in the register
of members of the Company in order to be entitled to attend and
vote at the meeting, was 1,141,999,321 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote
in law and is not counted in the calculation of the proportion of
the votes for and against it.
A copy of the resolutions passed has been submitted to the
National Storage Mechanism and will shortly be available for
inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGNKKBKPBKDAAN
(END) Dow Jones Newswires
June 30, 2023 11:07 ET (15:07 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024
